Marcel van Duin, PhD

Dr. Marcel van Duin is Chief Scientific Officer and responsible for External Innovation and Emerging Science at Organon, a company with the vision to advance the health of women.
Marcel was previously Vice President, Head of R&D Alliances for Reproductive Medicine and Maternal Health (RM&MH) and Therapeutic Area Head for Research in RM&MH at Ferring Pharmaceuticals and member of the global drug discovery leadership team. Key scientific focus was on projects for Endometriosis, Infertility and Obstetrical complications such as preterm labor and preeclampsia as well as a strong outreach to external opportunities.
Before that his career spanned leadership R&D responsibilities in multiple Women’s Health areas in Merck & Co, Schering Plough and Organon where he started his professional journey in the pharmaceutical industry in Oss, the Netherlands.
Marcel holds a B.S. in biology from Utrecht university and PhD at Erasmus university, Rotterdam, both in the Netherlands.
At present he holds an honorary professorship in Innovation at the Chinese Academy of Sciences in Beijing, China. He has (co-)authored over 60 scientific publications.

With a distinguished career in health care spanning more than thirty years, Jim is a Founder and Managing Partner of Tyree & D’Angelo Partners (TDP), a private equity firm focused on investments in promising, underperforming businesses in the lower-middle market.

Prior to founding TDP in 2012, Jim had an outstanding 15 year career at Abbott, holding executive positions in its pharmaceutical and nutrition businesses. Jim was involved in many of the company’s major acquisitions and was responsible for the restructuring of TAP, Abbott’s joint venture with Takeda Chemicals of Japan. Jim served as Executive Vice President, Pharmaceutical Products, Abbott’s largest business, and was also directly responsible for establishing and managing Abbott Global Nutrition, Abbott’s second largest operating division. Jim also served as President of Abbott Biotech Ventures. Prior to his career at Abbott, Jim was President of Sugen, Inc., a biotech company focused on oncology, and held management positions at Bristol-Myers Squibb and Pfizer.

Jim currently serves or has served as an independent director of a number of privately and publicly held companies. He is also a member of The Council of Advisors at the University of Chicago Graduate School of Business (Booth). He earned his MBA from the Kelley School of Business at Indiana University, as well as two bachelor degrees in psychology and forensic studies from Indiana University.

George Keefe served as SVP of Market Access and SVP of External Affairs and Public Policy during his 20 year career with Teva Pharmaceuticals. His leadership roles included Market Access, Government Affairs, Public Policy, Payer Marketing, Pricing and Contracting, Reimbursement Strategies, Patient Assistance and Medical Affairs. George served on Teva’s US and North America leadership teams from 2015 through 2021.

George joined Teva in 2002 where he took on various positions of increasing responsibility, assuming leadership of U.S. Market Access in 2015. George was involved with launching and commercializing dozens of products covering numerous therapeutic areas and digital health. In his most recent role, George led the Government Affairs, Public Policy and Medical Affairs functions. He helped to guide Teva’s advocacy efforts and represented Teva’s interests on a range of key issues. George worked with Congressional leaders, Members of Congress, key Administration officials and other policymakers on issues of critical importance to the industry.

George holds a Bachelor of Arts degree in Economics with a minor in Political Science from SUNY Geneseo and an MBA in Finance and Marketing from the University at Buffalo. He lives in Santa Rosa Beach, Florida with his wife Linda. George enjoys hiking, cycling, playing basketball and reading historical biographies of world leaders.

A medical device industry veteran with more than 25 years experience, Chip is currently founder and CEO of Regatta Medical, focusing on acquiring companies and assets in the products and services areas of the medical device industry.

Chip previously served as CEO of Creganna Medical, a leading Ireland-based supplier to the minimally invasive medical device industry. After a successful three year effort to focus the company on higher growth markets and improve operational performance, Creganna Medical was sold to TE Connectivity in 2016. Preceding Creganna, Chip was an Entrepreneur-in-Residence within the FDA at CDRH in 2012-13. He co-led the Innovation Pathway team focused on streamlining aspects of medical device clinical trials in the U.S.  Prior to his work at FDA, Chip had a long and distinguished career at Abbott, including President of Abbott Vascular, Abbott’s cardiovascular device division, where he led the organization from a small vessel closure business through acquisitions and organic growth to global leadership in the drug-eluting stent market with the launch of Xience in the U.S., Japan, and China. Abbott Vascular became a multi-billion dollar division of Abbott.

Chip earned a bachelor’s degree in Chemical Engineering from the Massachusetts Institute of Technology and a master’s degree in Business Administration from Harvard Business School.

Kirk Keaffaber leads Digital Health for the Biomedicines Division covering neurosciences and immunology. In this role, he has led the digital health strategy for the business unit, the first digital product to market from concept to commercialization, digital-first components of customer support, contributed to clinical digital health efforts, and established external collaborations for innovation. Prior to that he was Senior Director responsible for Commercial Strategy & Operations in Neurosciences, which included traditional activities, but also creating a digital health focus within the business unit. Prior to that, he led Integrated/Omni-Channel Marketing, building from a single brand to then become a large COE across all brands and business units for the US market. In his 21 years at Lilly, Kirk has held other leadership positions in global brand marketing, US customer marketing, and US Sales across many therapeutic areas, and also roles developing new commercial innovation.

Mr. Oldroyd has spent over 26 years in the healthcare industry.  His primary focus has been on startup organizations, building and executing business development and commercial strategies for new assets in therapeutics, diagnostics, real world data/AI engineering and software.  His expertise involves finding the best business use cases to generate revenue for new products in a large and challenging healthcare ecosystem.  He is currently the Chief Business Officer at C2i Genomics and sits on the Board of Directors at Base 10 Genetics.  Additionally, Mr. Oldroyd consults or advises a number of startup and larger organizations within the digital health, data security and diagnostic industries.  His education includes a Juris Doctor with a specialty in health law and policy.  Mr. Oldroyd spends much of his free time with his five adult children and two grandsons.  His other interests include aviation, as a private pilot, and adventure motorcycling.